The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment., PMID:23452415
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types., PMID:23460532
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice., PMID:26113085
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications., PMID:26137403
Functional expression of CD137 (4-1BB) on T helper follicular cells., PMID:26587331
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer., PMID:27496866
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody., PMID:27756788
4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells., PMID:28473315
Checkpoint Inhibition in Non-Hodgkin's Lymphoma., PMID:29065421
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies., PMID:29118009
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes., PMID:29133290
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab., PMID:30410017
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity., PMID:31105267
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells., PMID:31143521
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity., PMID:31974274
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma., PMID:32052473
4-1BB costimulation promotes bystander activation of human CD8 T cells., PMID:33180337
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development., PMID:34064598
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors., PMID:34168049
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic., PMID:34172583
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function., PMID:34580116
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes., PMID:35110355
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies., PMID:35236742
In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice., PMID:35820360
A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity., PMID:36076251
Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates., PMID:36176235
Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity., PMID:36248847
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary., PMID:36576322
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy., PMID:36727218
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents., PMID:37310433
A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma., PMID:37339979
4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T., PMID:37433196
FcγR requirements and costimulatory capacity of Urelumab, Utomilumab, and Varlilumab., PMID:37575254
Costimulatory capacity of CD137 mAbs on T cells depends on elaborate CRD structures but not on blocking ligand-receptor binding., PMID:37675596
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation., PMID:38091375
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma., PMID:38309721
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors., PMID:38458639
Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy., PMID:38492435
CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors., PMID:38593226
Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials., PMID:39106643
Development of a tumor-region-selective activation monoclonal antibody targeting the 4-1BB receptor for enhanced therapeutic efficacy and safety., PMID:39978521
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic, PMID: 34172583
4-1BB-Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells, PMID: 28473315
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types, PMID: 23460532
Functional expression of CD137 (4-1BB) on T helper follicular cells, PMID: 26587331
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8 + T Cell-Relevant Genes, PMID: 29133290
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications, PMID: 26137403
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development, PMID: 34064598
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment, PMID: 23452415
Phase I Study of Stereotactic Body Radiotherapy Plus Nivolumab and Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors, PMID: 34168049
Checkpoint Inhibition in Non-Hodgkin's Lymphoma, PMID: 29065421
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer, PMID: 27496866
4-1BB costimulation promotes bystander activation of human CD8 T cells, PMID: 33180337
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity, PMID: 31974274
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity, PMID: 31105267
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells, PMID: 31143521
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies, PMID: 29118009
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice, PMID: 26113085
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody, PMID: 27756788
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab, PMID: 30410017
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma, PMID: 32052473
For research use only. Not for human or drug use.
